Strategic Evolution of Zhifei Biological Products in the Post-Pandemic Era: A Financial and Operational Analysis

Lijia Lin *

Department of Management, Ocean University of China, Qingdao, China

* Corresponding Author Email: linlijia@stu.ouc.edu.cn

Abstract. In the evolving landscape of the pharmaceutical industry post-COVID-19, Zhifei Biological Products stands out for its strategic maneuvering and financial growth. This paper investigates Zhifei Biological Products' financial resilience and strategic initiatives, emphasizing its focus on vaccine development and metabolic disease treatments. Through financial report analysis, the study reveals Zhifei's significant expansion in key sectors including mRNA and RSV vaccines, alongside its strategic partnerships for Shingles and HPV vaccines. The company's adaptability in navigating market challenges, leveraging R&D investments, and strategic collaborations underlines its potential for sustained growth. The analysis sheds light on Zhifei's approach to diversifying its portfolio and enhancing its market position through innovation in vaccine technology. The findings highlight the importance of strategic flexibility and innovation in securing competitive advantage and driving growth in the post-pandemic era, offering valuable insights for stakeholders in the pharmaceutical industry.

Keywords: Zhifei Biological Products, Post-pandemic growth, Vaccine development, Strategic analysis, pharmaceutical innovation.

1. Introduction

In the post-pandemic era, China's pharmaceutical industry is witnessing notable innovation and strategic adjustments, driven by a surge in clinical trials and local molecule development, with support from a strong venture capital scene and advanced R&D, fueled by returning talents and contract organizations. However, the sector confronts challenges including market access delays, pricing pressures, supply chain risks, and talent shortages, pushing towards digitalization for better efficiency and a move to reshore manufacturing to lessen foreign dependence amidst regulatory and investment challenges.

In examining the broader pharmaceutical landscape post-COVID-19, several studies illuminate the industry's adaptability and strategic redirection. Voronkova et al. employ a multi-faceted approach to assess the medicinal plant industry, spotlighting Russia's positioning within the global market and the pivotal role of state regulation and international cooperation in harnessing environmental assets for medicinal raw materials. Their findings emphasize the necessity for strategic planning in addressing industry-wide challenges and unlocking potential opportunities in the post-pandemic era [1].

Similarly, et al. delve into the strategic patterns of pharmaceutical firms, contrasting the benefits of focusing on specific therapeutic areas for smaller companies against the advantages of regional expansion for larger entities. Their analysis, covering strategies from 2004 to 2018, predicts a shift towards more targeted approaches spurred by diminishing R&D productivity, offering insights into strategic planning for sustainable industry growth [2]. Rathi et al. explored the accelerated adoption of AI in pharmaceutical innovation, employing patent analysis to uncover a rise in AI-related advancements. Their research indicates a pandemic-driven boost in AI integration, highlighting its role in streamlining the drug discovery process and enhancing innovation efficiency [3].

In analyzing the challenges and strategic responses to COVID-19, Cano-Marin et al. leverage social media analytics to dissect vaccine supply chain issues, revealing crucial regional disparities and the urgent need for better coordination for equitable vaccine access [4]. Similarly, Pessot and Albini delve into the pandemic's disruptions on pharmaceutical supply chains with a case study from

Italy, emphasizing the effectiveness of buffering and bridging strategies in building supply resilience [5]. Their findings suggest pathways for Chinese pharmaceuticals to fortify against such disruptions through strategic adaptability and robust supplier relationships. Meanwhile, Salem et al. extend the discussion to the construction industry in Kuwait, pinpointing delays, increased costs, and labor shortages as significant challenges [6]. They advocate for comprehensive recovery strategies, including strict adherence to health guidelines and the adoption of digital technologies to counter productivity setbacks, underlining the broader applicability of these strategies across sectors for enhancing post-pandemic resilience and efficiency.

Focusing on Zhifei Biological Products specifically, the studies by some researchers offer a micro-level perspective on the company's strategic navigations [7-9]. Wang's analysis of Zhifei's collaboration with GSK for Shingles vaccine distribution in China underscores the strategic benefits of such partnerships, predicting enhanced market performance and profitability due to high market potential and minimal competition [7]. Lou and Yang evaluate Zhifei's dual strategy of internal development and exclusive distribution, pointing to its effective positioning in the competitive vaccine market and its robust financial health as key to future growth [8]. Conversely, Sun critiques Zhifei's heavy reliance on agency business, particularly with Merck for HPV vaccines, suggesting a need for a more balanced approach between agency and self-developed vaccines for sustainable growth [9].

Liu's comparative analysis between Zhifei and Jiuan Medical against the economic downturn backdrop offers insights into Zhifei's growth and challenges, noting its reliance on the HPV vaccine monopoly but also its vulnerability to market dynamics [10]. Zhao's financial scrutiny through the Harvard Analysis Framework paints a detailed picture of Zhifei's financial health and strategic positioning, acknowledging the company's market opportunities while advising on bolstering R&D efforts and addressing potential financial risks [11].

These studies collectively navigate the post-pandemic pharmaceutical landscape from a macro to a micro perspective, highlighting the industry's strategic shifts and focusing on Zhifei Biological Products' specific responses. Building on previous insights into the pharmaceutical industry's evolution post-pandemic, this paper aims to delve into Zhifei Biological Products' strategic responses and growth trajectory in 2023, analyzing its financial performances and new growth points post-pandemic.

2. Financial Analysis of Zhifei Biological Products Co., Ltd.

2.1. Company Introduction

Founded in 2002, Chongqing Zhifei Biological Products Co., Ltd. specializes in vaccine and biological product development, manufacturing, and distribution worldwide. With a focus on infectious disease prevention, Zhifei's portfolio targets 11 conditions including meningitis, cervical cancer, and pneumonia, serving all age groups. Benefiting from the increased demand for vaccines during the COVID-19 pandemic, Zhifei is now exploring new growth avenues in the post-pandemic era of 2023, aiming to expand its impact on public health. The following analysis will examine Zhifei's financial performance, focusing on its strategic initiatives for growth beyond the pandemic.

2.2. Operating Revenue and Costs Analysis

Between 2019 and 2022, Zhifei Biological Products experienced a revenue jump from 10.59 billion CNY to 38.26 billion CNY, primarily due to heightened vaccine demand during the COVID-19 pandemic (Fig. 1). In this period, operational and production costs also increased from 7.71 billion CNY to 29.05 billion CNY, reflecting expanded activities to meet vaccine demand. Concurrently, R&D spending surged from 0.1696 billion CNY to 0.8542 billion CNY, showcasing Zhifei's commitment to innovation and its strategic aim to diversify its product offerings for long-term growth (Fig. 2).




Figure 1. Total Operating Revenue and Costs 2019-2022




Figure 2. R&D Expenses (Billion) 2019-2022

Post-COVID, Zhifei's continued revenue growth was spurred by strategic diversification of its product portfolio and significant investments in R&D. The company's operational excellence and market adaptability, evidenced by a 33.19% increase in revenue compared to the same period last year, positions Zhifei for ongoing growth and leadership in the biopharmaceutical industry (Fig. 3). Moving beyond COVID-19 vaccines, Zhifei expanded its offerings to include a variety of preventive vaccines and therapeutic bioproducts for diseases like meningitis, cervical cancer, pneumonia, and rotavirus. This expansion allowed the company to cater to broader healthcare needs, sustaining its revenue growth momentum.

In the first half of 2023, Zhifei showcased remarkable financial performance, driven by its diverse product portfolio and strategic R&D investments. With a substantial R&D investment totaling 0.4369 billion CNY in the first half of 2023, representing 67.84% of revenue from proprietary products and marking a 12.55% increase from the previous year. The expansion of the R&D team by 26.43% to 818 personnel and the advancement of 30 R&D projects, including 17 in clinical trials and registration stages, underscore Zhifei's dedication to innovation (Fig. 4). This strategic emphasis on R&D is crucial for developing a robust pipeline of vaccines and therapeutic products that cater to a broad spectrum of diseases.




Figure 3. Total Operating Revenue and Costs 2023 Q1-Q3




Figure 4. R&D Expenses(Billion) 2023 Q1-Q3

Zhifei's strategic developments, including the partnership with GSK for the distribution of Shingrix and significant financial growth, underscore the company's long-term vision. The continuous uptick in R&D investment positions Zhifei at the forefront of the biopharmaceutical sector, poised to lead in the discovery and development of new vaccines and therapeutic solutions. This approach not only secures Zhifei's market position but also drives its sustained success in the rapidly evolving global biopharmaceutical landscape.

Furthermore, Zhifei leveraged strategic government policies and international expansion to bolster its market position. Supportive policies from the Chinese government, aimed at strengthening the biopharmaceutical sector, alongside efforts to forge global partnerships, contributed to Zhifei's sustained revenue growth. The establishment of a robust marketing and distribution network further facilitated the wide availability and accessibility of Zhifei's products, enhancing market penetration.

2.3. Operating Profit Analysis Based on Sectors

From 2020 to 2022, Zhifei Biological Products navigated the pandemic's market dynamics with strategic agility, significantly impacting its financial metrics across agency and proprietary products. Operating profits for agency products surged from 4.884 billion CNY in 2020 to 10.025 billion CNY in 2022, highlighting effective market penetration and demand fulfillment. Conversely, proprietary products saw a peak in 2021 at 8.739 billion CNY, with a subsequent decrease to 2.841 billion CNY in 2022, reflecting fluctuating R&D investment returns (Fig. 5).

Gross margin analysis revealed a decrease in agency products from 34.91% in 2020 to 28.66% in 2022, suggesting rising operational costs or strategic pricing adjustments. Proprietary products, however, consistently exhibited high gross margins, slightly dipping from 90.12% in 2021 to 86.48% in 2022, still underscoring the high profitability of Zhifei's in-house innovations (Fig. 6).

Profitability analysis from 2019 to 2022 shows ROE peaking at 78.01% in 2021 and then normalizing to 36.13% in 2022, with ROA and Net Profit Margin depicting similar trends. This period illustrates Zhifei's success in leveraging the pandemic-induced demand, followed by a stabilization of financial performance as market conditions began to normalize.




Figure 5. Main Operating Profit by Sectors




Figure 6. Gross Profit Margin By Sectors

Post-pandemic, Zhifei adeptly navigated the shifting dynamics of the biopharmaceutical industry, focusing on sustaining growth and profitability into 2023. This period was characterized by a strategic blend of continuing proxy sales, notably with Merck, and amplifying investments in research and development (R&D) for proprietary products. Such a balanced approach underscores Zhifei's agility in capitalizing on immediate market opportunities while laying the groundwork for long-term innovation and market presence.

The company's financial performance, particularly in the gross profit margins of agency versus proprietary products, reflects this strategic posture. By the end of 2022, Zhifei had achieved a gross profit margin of 33.63%, which adjusted to a range of 28.27% to 30.30% across the first three quarters of 2023. The differentiation between agency products, with a gross margin of 27.46%, and proprietary products, at an impressive 86.74%, illustrates the latter's significant contribution to profitability. This variance not only highlights the robust returns on Zhifei's R&D endeavors but also the strategic importance of its partnership with Merck in stabilizing revenue streams.

Analyzing Zhifei's profitability metrics further, the Return on Equity (ROE) and Return on Assets (ROA) experienced notable changes from 2022 to 2023. The ROE, peaking at 36.13% in 2022, saw a range between 8.05% and 16.32% in the following quarters, suggesting a normalization of equity efficiency post-pandemic. Similarly, the ROA decreased from 22.16% in 2022 to between 5.00% and 9.92% in 2023, indicating a steady improvement in utilizing assets to generate profit. The Net Profit Margin also reflected a modest decline from 19.70% in 2022 to between 16.63% and 18.19% in 2023, underscoring consistent revenue conversion into net income amidst evolving market conditions.

The post-pandemic era posed unique challenges and opportunities for Zhifei Biopharmaceutical, prompting a strategic recalibration towards balancing the immediate benefits derived from agency sales against the long-term potential of proprietary product innovation. This dual strategy not only facilitated Zhifei in leveraging the pandemic-induced demand surge but also positioned the company for sustainable growth. Through careful management of its diversified product portfolio and a keen focus on R&D, Zhifei continues to strengthen its competitive advantage, demonstrating a commitment to innovation and strategic growth in the global biopharmaceutical market.

2.4. Operational Efficiency

Between 2020 and 2022, Zhifei Biological Products navigated through periods of varying operational efficiency. In this timeframe, Total Asset Turnover Days rose slightly from 310.0 days in 2020 to 320.1 days by 2022, indicating a gradual slowdown in the company’s ability to convert assets into revenue. Meanwhile, Inventory Turnover Days showcased an improvement, moving from 114.4 days to 109.2 days across the same period, reflecting better inventory management practices (Fig. 7).

In 2023, Zhifei demonstrated a remarkable enhancement in operational efficiency, especially notably post-pandemic. By the end of Q3 2023, Total Asset Turnover Days had improved significantly to 300.0 days, down from 320.1 days in 2022, evidencing a more efficient use of assets in generating revenue. This marked improvement in 2023 suggests that Zhifei strategically refined its

asset management and operational processes, possibly through digital transformation initiatives or optimizing operational workflows, to better align with post-pandemic market dynamics. Furthermore, Inventory Turnover Days decreased significantly to 88.32 days by Q3 2023, from 109.2 days in 2022, highlighting the company's enhanced capability in inventory management (Fig. 7). This improvement likely results from Zhifei's focused efforts on supply chain optimization and demand forecasting, ensuring a swift response to market needs and minimizing inventory excesses.




Figure 7. Inventory and Total Asset Turnover Days 2019-2023

2.5. Liquidity Analysis

Throughout 2019 to 2022, Zhifei Biological Products demonstrated a progressive enhancement in liquidity, evidenced by the rise in Current Ratio from 1.610 in 2019 to 2.374 in 2022, and an increase in Quick Ratio from 1.120 to 1.768 over the same period. These improvements signal a strengthening ability to meet short-term obligations and an enhanced capacity to cover liabilities without resorting to inventory sales, showcasing prudent liquidity management (Fig. 8).

In the transition to 2023, the liquidity ratios experienced slight fluctuations, with the Current Ratio slightly decreasing to 2.099 in Q2 before recovering to 2.257 by Q3. Similarly, the Quick Ratio saw a decrease to 1.515 in Q2 2023, followed by an improvement to 1.698 by Q3 2023(Fig. 8). These movements suggest a temporary challenge in liquidity during the early months of 2023, likely due to operational investments or shifts in market dynamics post-pandemic. However, the rebound in these ratios by Q3 2023 indicates Zhifei's effective adjustment and ongoing capacity to manage its short-term financial commitments.

The observed fluctuations in 2023 and subsequent recovery highlight Zhifei's strategic approach to liquidity management in a post-pandemic environment. By Q3 2023, the company not only navigated through the temporary liquidity constraints but also showcased its resilience by improving its liquidity position. This adaptability is crucial in the biopharmaceutical sector, where financial stability supports operational goals and strategic investments amidst market volatility.




Figure 8. Current Ratio and Quick Ratio 2019-2023

2.6. Financial Stability

From 2019 to 2022, Zhifei Biological Products strategically enhanced its financial stability, evidenced by a decrease in the Debt-to-Equity Ratio from 47.48% to 36.23%, indicating reduced debt

reliance. The Equity Coefficient slightly declined from 1.904 to 1.568, showing a strong equity base amidst a nuanced shift towards some debt financing for growth (Fig. 9).

In 2023, the Debt to Equity Ratio saw a temporary peak at 42.13% in Q2, adjusting to 39.18% by Q3, reflecting short-term debt utilization for expansion, followed by a strategic rebalance. The Equity Coefficient increased to 1.728 in Q2 and adjusted to 1.644 in Q3, mirroring the company's strategy to recalibrate its financing approach(Fig. 9).

Post post-pandemic period reflects Zhifei's careful balance between debt leverage and maintaining a solid equity foundation, demonstrating a strategic financial management to support growth while ensuring long-term financial stability. The 2023 adjustments highlight Zhifei's agility in optimizing its capital structure, crucial for sustaining operational success and strategic growth in the biopharmaceutical industry.




Figure 9. Debt to Equity Ratio and Equity Coefficient 2019-2023

3. Growth Point

Zhifei Biological Products' post-pandemic expansion focuses on five key areas: mRNA and RSV vaccines, Shingles and HPV vaccines, and metabolic disease treatments. This strategy emphasizes innovation in vaccine development, public health contributions, and strategic partnerships. By tapping into advanced vaccine technologies and branching into metabolic diseases, Zhifei aims to improve global health outcomes, bolster its market stance, and diversify its portfolio.

3.1. mRNA Vaccine

In the post-pandemic era, the mRNA vaccine market has surged, marked by the success of Pfizer/BioNTech and Moderna's COVID-19 vaccines, with sales exceeding $300 billion by March 2024. This success extends to the development of vaccines for other diseases, like RSV, showcasing mRNA technology's potential beyond COVID-19. Zhifei Biological Products has strategically entered this promising sector through collaborations and its R&D efforts in mRNA vaccine technology for COVID-19 and RSV. A notable partnership with GSK on the RSV vaccine Arexvy, achieving significant sales, underscores Zhifei's commitment to leveraging global advancements for domestic innovation. This strategic move positions Zhifei to capitalize on the growing mRNA vaccine market, enhancing its industry competitiveness and contributing to global public health advancements.

3.2. Shingles Vaccine

The Shingles vaccine market, marked by low penetration rates in China and significant demographic trends, presents a substantial growth opportunity for Chongqing Zhifei Biological Products. Zhifei's strategic collaboration with GSK for the distribution of Shingrix in 2024 is a key move to capitalize on this expanding market. With a minimum annual purchase commitment of 3.44 billion CNY for 2024 and exclusive distribution rights, Zhifei is set to enhance its market position. The high efficacy of Shingrix and its approval for individuals aged 50 and above provide a competitive edge. This partnership not only bolsters Zhifei's vaccine portfolio but also opens doors

for further growth and collaborations, notably in the RSV vaccine domain, positioning Zhifei for sustained industry leadership and growth.

3.3. HPV vaccine

The HPV vaccine market is a key growth area, driven by increasing cervical cancer cases in China and global elimination goals. China's approval of five HPV vaccine types, including Gardasil 9 for a broader age range, signifies market expansion. In 2023, the sector saw a 15.1% increase in vaccine batch approvals, with a notable surge in demand for the nonavalent vaccine. Merck's strategic updates, including an expanded age range and a two-dose regimen, have sparked competitive pricing dynamics, significantly impacting the market. Zhifei Biological Products, by incorporating HPV vaccines into its portfolio, aligns with national health goals and taps into this growth sector, enhancing its commitment to public health and leveraging new opportunities in cancer prevention.

3.4. Rabies vaccine

Post-COVID-19, China's rabies vaccine sector is set for growth, driven by an urgent need to combat the high fatality of rabies and a low vaccination rate among the 40 million annually exposed, partly due to an expanding pet population. The market, which saw a decline in demand due to quality concerns and reduced outdoor activities, is expected to rebound with the easing of pandemic restrictions. Despite a temporary 48.1% drop in vaccine batch issuance in Q4 2023, the sector's growth prospects remain robust, supported by nearly 20 approved rabies vaccines as of September 2023. Chongqing Zhifei Biological Products is poised to address this demand with its freeze-dried human rabies vaccine (MRC-5 cell), marking a strategic expansion in its infectious disease prevention portfolio and reinforcing its commitment to public health in China.

3.5. Metabolic Diseases

In November 2023, Zhifei Biological Products acquired Chenan Biotech, venturing into the metabolic disease sector, notably diabetes and obesity. This strategic move, executed for 100% equity through a cash transaction, diversifies Zhifei's portfolio into a market ripe with demand for advanced treatments. Chenan's pipeline includes promising GLP-1 analog drugs, with recombinant liraglutide and Degludec insulin injections completing Phase III trials, and a recombinant semaglutide injection progressing through the same phase. This acquisition, coupled with a 3 billion CNY investment in Chenan’s industrialization project aiming for an 80 million annual unit output, underscores Zhifei's commitment to scaling production to meet growing market needs. Through this acquisition, Zhifei broadens its therapeutic impact, targeting significant public health issues and enhancing its market competitiveness in the metabolic disease arena.

4. Suggestions and Inspirations

Zhifei Biological Products' strategy post-pandemic in 2023 serves as a guiding light for other enterprises and investors, emphasizing the importance of agility and innovation in navigating the evolving biopharmaceutical landscape.

For enterprises, Zhifei's substantial investments in research and development (R&D), particularly in cutting-edge sectors like mRNA vaccines and metabolic diseases, underscore the value of prioritizing innovation to ensure long-term competitiveness and market relevance. Additionally, Zhifei's ability to balance agency sales with the development and marketing of proprietary products demonstrates a successful dual-market strategy that can be crucial for revenue diversification and risk management.

Investors, on the other hand, can glean from Zhifei's approach that backing companies with a strong focus on R&D and strategic expansions into high-growth areas presents a promising avenue for sustained returns. Zhifei's diversified approach—spanning strategic acquisitions, partnerships,

and continuous product portfolio expansion—highlights the importance of investing in companies that are not only adaptable to market shifts but also proactive in capitalizing on new opportunities.

In essence, Zhifei's post-pandemic actions reveal a strategic blueprint for thriving in the biopharmaceutical industry. The emphasis on R&D, coupled with a robust marketing strategy and strategic collaborations, points to a path of resilience and growth. Both enterprises looking to navigate the post-pandemic market dynamics and investors seeking resilient, innovative firms would do well to consider these insights as they plan their strategies moving forward.

5. Conclusion

In 2023, Zhifei Biological Products exemplified a strategic blueprint for navigating the post-pandemic biopharmaceutical landscape. Its commitment to R&D, expansion across new markets, and strategic partnerships significantly propelled its growth and bolstered both operational and financial performance. Zhifei's strategy underscores the criticality of innovation, market adaptability, and financial management for enduring success.

Zhifei Biological Products' strategic expansion in 2023 showcases a dual focus on broadening its product lineup with substantial R&D investments and maintaining operational and financial discipline. By diversifying its portfolio beyond COVID-related vaccines to include a broader range of biopharmaceutical products, Zhifei emphasizes its dedication to innovation, setting the stage for long-term growth. Concurrently, the company has demonstrated financial resilience and operational efficiency, underpinned by strategic financial management. This includes optimizing liquidity ratios and managing a balanced debt-to-equity ratio, coupled with improvements in operational metrics. These combined efforts highlight Zhifei's preparedness for future challenges and opportunities, marking a significant stride toward sustainable advancement in the biopharmaceutical sector.

In conclusion, Zhifei Biological Products' strategies in the aftermath of the pandemic serve as a valuable model for resilience and strategic foresight in the biopharmaceutical sector. The company's balanced approach to R&D, market diversification, and financial health not only propels its own growth but also offers key lessons for other enterprises and investors. This narrative emphasizes the importance of innovation, market adaptability, and financial stability as cornerstones for thriving in the post-pandemic era, setting a benchmark for strategic excellence in the industry.

References

[1] Voronkova, O. Y., Volokhova, T. V., Lebedeva, E. S., Smirnova, A. V., & Tubalets, A. A. (2022). Priorities for the Development of Medicinal Plant Growing in a Post-Pandemic Environment. Siberian Journal of Life Sciences and Agriculture, 14 (1), 436 - 451.

[2] Nakashima, A., Kodama, K., & Sengoku, S. (2023). Strategic trends of pharmaceutical companies: A growth model through regional focus and inter-regional alliances. Drug Discovery Today, 28 (7).

[3] Rathi, S., Majumdar, A., & Chatterjee, C. (2024). Did the COVID-19 pandemic propel usage of AI in pharmaceutical innovation? New evidence from patenting data. Technological Forecasting and Social Change, 198, 122940.

[4] Cano-Marin, E., Ribeiro-Soriano, D., Mardani, A., & Blanco Gonzalez-Tejero, C. (2023). Exploring the challenges of the COVID-19 vaccine supply chain using social media analytics: A global perspective. Sustainable Technology and Entrepreneurship, 2, 100047.

[5] Pessot, E., & Albini, T. (2023). COVID-19 Pandemic Impacts and Long-Term Supply Strategies of Pharmaceutical Manufacturers. In Borgianni, Y., Matt, D.T., Molinaro, M., & Orzes, G. (Eds.), Towards a Smart, Resilient, and Sustainable Industry. ISIEA 2023. Lecture Notes in Networks and Systems, vol 745. Springer, Cham.

[6] Salem, M., Kirkham, R., Al-Sabah, R., & Chebli, S. (2023). COVID-19 and the construction sector: Impacts and an agenda for post-pandemic policy in the context of Kuwait. Journal of Engineering Research.

[7] Wang, B. G. (2023). Zhifei Biological Products: Strategic cooperation with GSK and exclusive agency of shingles vaccine. Stock Market Dynamics Analysis, (21), 35 - 35.

[8] Lou, S., & Yang, H. (2021). Zhifei Biological Products: Driven by both self-research and agency, a promising future.

[9] Sun, Y. (2019). Dependency on agency: How far can Zhifei Biological Products fly? Talents, (11), 2.

[10] Liu, C. R. (2022). The rise and challenges of Zhifei Biological Products in the vaccine market. Talents, (6), 66 - 68.

[11] Zhao, Y. (2019). Financial statement analysis of Zhifei Biological Products based on the Harvard Analysis Framework (Doctoral dissertation, Jilin University).